Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.54 |
| ▸ | PYGL | P06737 | 11/20 | 0.49 |
| ▸ | PYGM | P11217 | 9/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.48 |
| ▸ | NHERF1 | O14745 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4266511 | 0.86 | SMYD3 (0.47) | SMYD3PYGLPYGMF10EHMT2 | |
| SCHEMBL2939103 | 0.86 | SMYD3 (0.47) | SMYD3PYGLPYGMF10EHMT2 | |
| SCHEMBL12035628 | 0.86 | SMYD3 (0.55) | SMYD3PYGLPYGMF7F3 | |
| SCHEMBL12833090 | 0.86 | SMYD3 (0.60) | SMYD3PYGLPYGMF7F3 | |
| SCHEMBL1503949 | 0.84 | PYGL (0.53) | SMYD3PYGLPYGMF7F3 | |
| SCHEMBL2936241 | 0.84 | PYGL (0.53) | SMYD3PYGLPYGMF7F3 | |
| SCHEMBL1503952 | 0.84 | PYGL (0.53) | SMYD3PYGLPYGMF7F3 | |
| SCHEMBL2939104 | 0.80 | PYGL (0.47) | SMYD3PYGLPYGMEHMT2HRH4 | |
| SCHEMBL4363306 | 0.79 | SMYD3 (0.63) | SMYD3PYGLF7F3F10 | |
| SCHEMBL4360291 | 0.79 | SMYD3 (0.63) | SMYD3PYGLF7F3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270446-A1 | DIAMINE DERIVATIVES | F2, TFPI, F3 | SMYD3 2701/4885PYGL 1509/4885PYGM 4078/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | SMYD3 3513/4885PYGL 3803/4885PYGM 4064/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | SMYD3 3513/4885PYGL 3803/4885PYGM 4064/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | SMYD3 3513/4885PYGL 3803/4885PYGM 4064/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | SMYD3 2701/4885PYGL 1509/4885PYGM 4078/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | SMYD3 3337/4885PYGL 3866/4885PYGM 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.